Antimicrobial resistance dynamics in

Jie Dai, Fanglin Zeng, Fengyue Hu, Xin Mao, Wenjuan Guo, Weili Liu, Jinfu Wang, Changjiao Luan

Abstract read

In one paragraph

Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jie DaiDepartment of Clinical Laboratory, The Third People's Hospital of Yangzhou, Yangzhou, China.

Fanglin ZengDepartment of Clinical Laboratory, The Third People's Hospital of Yangzhou, Yangzhou, China.

Fengyue HuDepartment of Clinical Laboratory, The Third People's Hospital of Yangzhou, Yangzhou, China.

Xin MaoDepartment of Lung, The Third People's Hospital of Yangzhou, Yangzhou, China.

Wenjuan GuoDepartment of Clinical Laboratory, The Third People's Hospital of Yangzhou, Yangzhou, China.

Weili LiuLaboratory of Intensive Care, Laboratory for Prevention and Translation of Geriatric Diseases, The Affiliated Hospital of Yangzhou University, Yangzhou, China.

Jinfu WangDepartment of Clinical Laboratory, The Third People's Hospital of Yangzhou, Yangzhou, China.

Changjiao LuanDepartment of Lung, The Third People's Hospital of Yangzhou, Yangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secondary pulmonary infections are crucial and pivotal contributing factors to clinical deterioration in patients with pulmonary tuberculosis. Research remains limited regarding the specific population and regional epidemiology of these secondary infections, despite its clinical importance. This study provides an in-depth analysis of the primary bacterial pathogens and their antimicrobial resistance rates among hospitalized pulmonary tuberculosis patients with concurrent pulmonary infections in Yangzhou, China, from 2021 to 2024. Suitable sputum samples and leftover bronchoalveolar lavage fluid samples were collected for bacterial culture identification and drug sensitivity testing. The annual and regional distributions of strains and the evolution of resistance rates were analyzed using the chi-square test and the Cochran-Armitage trend test. A total of 514 strains of pathogenic bacteria were cultured from 410 samples, with 499 strains (97.08 %) being Gram-negative bacteria.

Indexed as

Bacterial resistanceMicrobial genus distributionPulmonary infectionPulmonary tuberculosis

Identifiers

PMID41769068

DOI10.1016/j.bbrep.2026.102474

PMCPMC12937013

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.